Search research articles
Contact Us
Filters
Showing results (31-40 of 45) with videos related to
Page
of 5
Sort By:
Inflammatory Bowel Diseases
|
December 10, 2024
Mediators of Filgotinib Treatment Effects in Ulcerative Colitis: Exploring Circulating Biomarkers in the Phase 2b/3 SELECTION Study
Hiroshi Nakase, Silvio Danese, Walter Reinisch, et al.
The Lancet. Gastroenterology & Hepatology
|
November 19, 2021
Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study
Severine Vermeire, Peter L Lakatos, Timothy Ritter, et al.
The American Journal of Gastroenterology
|
September 16, 2022
Rapid and Sustained Symptom Relief in Patients With Ulcerative Colitis Treated With Filgotinib: Data From the Phase 2b/3 SELECTION Trial
Silvio Danese, Marc Ferrante, Brian G Feagan, et al.
International Journal of Radiation Oncology, Biology, Physics
|
October 12, 2010
Consideration of dose limits for organs at risk of thoracic radiotherapy: atlas for lung, proximal bronchial tree, esophagus, spinal cord, ribs, and brachial plexus
Feng-Ming Spring Kong, Timothy Ritter, Douglas J Quint, et al.
JAMA Oncology
|
June 2, 2017
Effect of Midtreatment PET/CT-Adapted Radiation Therapy With Concurrent Chemotherapy in Patients With Locally Advanced Non-Small-Cell Lung Cancer: A Phase 2 Clinical Trial
Feng-Ming Kong, Randall K Ten Haken, Matthew Schipper, et al.
Clinical and Translational Gastroenterology
|
December 22, 2023
Clinical Long-Term Outcomes of Patient-Reported Outcomes in the Prospective Real-World Tofacitinib Response in Ulcerative Colitis Registry
Hans H Herfarth, Anita Afzali, Monika Fischer, et al.
Gastroenterology
|
March 20, 2025
Efficacy and Safety of Guselkumab Subcutaneous Induction and Maintenance in Participants With Moderately to Severely Active Crohn's Disease: Results From the Phase 3 GRAVITI Study
Ailsa Hart, Remo Panaccione, Flavio Steinwurz, et al.
Inflammatory Bowel Diseases
|
June 14, 2022
Tofacitinib Response in Ulcerative Colitis (TOUR): Early Response After Initiation of Tofacitinib Therapy in a Real-world Setting
Millie D Long, Anita Afzali, Monika Fischer, et al.
Annals of the Rheumatic Diseases
|
May 3, 2023
Effects of filgotinib on semen parameters and sex hormones in male patients with inflammatory diseases: results from the phase 2, randomised, double-blind, placebo-controlled MANTA and MANTA-RAy studies
Walter Reinisch, Wayne Hellstrom, Radboud J E M Dolhain, et al.
The Lancet. Gastroenterology & Hepatology
|
December 5, 2024
Efficacy and safety of filgotinib as induction and maintenance therapy for Crohn's disease (DIVERSITY): a phase 3, double-blind, randomised, placebo-controlled trial
Séverine Vermeire, Stefan Schreiber, David T Rubin, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 45) with videos related to
Sort By:
Page
of 5
Inflammatory Bowel Diseases
|
December 10, 2024
Mediators of Filgotinib Treatment Effects in Ulcerative Colitis: Exploring Circulating Biomarkers in the Phase 2b/3 SELECTION Study
Hiroshi Nakase, Silvio Danese, Walter Reinisch, et al.
The Lancet. Gastroenterology & Hepatology
|
November 19, 2021
Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study
Severine Vermeire, Peter L Lakatos, Timothy Ritter, et al.
The American Journal of Gastroenterology
|
September 16, 2022
Rapid and Sustained Symptom Relief in Patients With Ulcerative Colitis Treated With Filgotinib: Data From the Phase 2b/3 SELECTION Trial
Silvio Danese, Marc Ferrante, Brian G Feagan, et al.
International Journal of Radiation Oncology, Biology, Physics
|
October 12, 2010
Consideration of dose limits for organs at risk of thoracic radiotherapy: atlas for lung, proximal bronchial tree, esophagus, spinal cord, ribs, and brachial plexus
Feng-Ming Spring Kong, Timothy Ritter, Douglas J Quint, et al.
JAMA Oncology
|
June 2, 2017
Effect of Midtreatment PET/CT-Adapted Radiation Therapy With Concurrent Chemotherapy in Patients With Locally Advanced Non-Small-Cell Lung Cancer: A Phase 2 Clinical Trial
Feng-Ming Kong, Randall K Ten Haken, Matthew Schipper, et al.
Clinical and Translational Gastroenterology
|
December 22, 2023
Clinical Long-Term Outcomes of Patient-Reported Outcomes in the Prospective Real-World Tofacitinib Response in Ulcerative Colitis Registry
Hans H Herfarth, Anita Afzali, Monika Fischer, et al.
Gastroenterology
|
March 20, 2025
Efficacy and Safety of Guselkumab Subcutaneous Induction and Maintenance in Participants With Moderately to Severely Active Crohn's Disease: Results From the Phase 3 GRAVITI Study
Ailsa Hart, Remo Panaccione, Flavio Steinwurz, et al.
Inflammatory Bowel Diseases
|
June 14, 2022
Tofacitinib Response in Ulcerative Colitis (TOUR): Early Response After Initiation of Tofacitinib Therapy in a Real-world Setting
Millie D Long, Anita Afzali, Monika Fischer, et al.
Annals of the Rheumatic Diseases
|
May 3, 2023
Effects of filgotinib on semen parameters and sex hormones in male patients with inflammatory diseases: results from the phase 2, randomised, double-blind, placebo-controlled MANTA and MANTA-RAy studies
Walter Reinisch, Wayne Hellstrom, Radboud J E M Dolhain, et al.
The Lancet. Gastroenterology & Hepatology
|
December 5, 2024
Efficacy and safety of filgotinib as induction and maintenance therapy for Crohn's disease (DIVERSITY): a phase 3, double-blind, randomised, placebo-controlled trial
Séverine Vermeire, Stefan Schreiber, David T Rubin, et al.
Page
of 5